Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Pain, Postoperative
Interventions: XaraColl, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 24
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more

Conditions: Keratoconus
Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment; Combination Product
Lead sponsor: Epion Therapeutics; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: S-707106, Placebo, Metformin, S-707106 plus metformin, Metformin, placebo plus metformin; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Wilson Disease
Interventions: UX701, Standard of Care (SOC); Genetic · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • Sacramento, California + 9 more

Conditions: Obesity
Interventions: maridebart cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Anaheim, California • Tustin, California • Miami, Florida

Conditions: Non-infectious Uveitis
Interventions: Basiliximab, Placebo; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more

Conditions: Rheumatoid Arthritis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 38
States / cities: Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 33 more

Conditions: Diabetes Mellitus
Interventions: Alogliptin, Pioglitazone, Metformin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more

Conditions: Coronary Heart Disease
Interventions: MPSK3169A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 34
States / cities: Goodyear, Arizona • Carmichael, California • Spring Valley, California + 29 more

Conditions: Knee Arthropathy
Interventions: Percutaneous peripheral nerve stimulation; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo (for MN-166), MN-166, riluzole; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cognition Disorders, HIV Infections
Interventions: Selegiline hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Honolulu, Hawaii + 10 more

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: INOpulse®, Placebo, Open Label Extension; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Bryant, Arkansas • Bellflower, California • Glendale, California + 31 more

Conditions: Hyperhidrosis
Interventions: WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg, WL8713, 24 mg, Placebo; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Fibromyalgia
Interventions: Placebo, Milnacipran; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more

Conditions: Endometriosis
Interventions: Proellex 25 mg, Placebo, Proellex 50 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 13 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: Investigational RSV vaccine 1, Investigational RSV vaccine 2, Investigational RSV vaccine 3, Investigational RSV vaccine 4, Investigational RSV vaccine 5, Investigational RSV vaccine 6, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 5
States / cities: Rolling Hills Estates, California • Atlanta, Georgia • Lenexa, Kansas + 2 more

Conditions: Heavy Menstrual Bleeding
Interventions: Juveena Hydrogel System; Device
Lead sponsor: Rejoni Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Little Rock, Arkansas • West Orange, New Jersey • Cincinnati, Ohio

Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma, Primary Mediastinal B-cell Lymphoma
Interventions: JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 14
States / cities: Birmingham, Alabama • Duarte, California • San Francisco, California + 10 more

Conditions: Conventional Chondrosarcoma
Interventions: IPI-926, Placebo Arm; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 11 more

Conditions: Healthy Volunteer Study
Interventions: Xenon gas inhalation; Drug
Lead sponsor: General Biophysics LLC; Industry
Eligibility: 55 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Female Orgasmic Disorder
Interventions: Placebo, Low dose TBS-2, Medium dose TBS-2, High dose TBS-2; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 37 more

Search by objective public record fields.

Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)

Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Knee Surgery

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder